URMC / Research / Health Research /Clinical Trials / Study Details

Expanded Access Program of Ponatinib

Basic Study Information

Purpose:
This protocol will allow expanded access of ponatinib to patients ≥18 years with chronic myeloid leukemia (CML) any phase or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who have failed all available treatment options.

Location: University of Rochester, Site 137

Study Contact Information

Additional Study Details

Contact This Study

First Name *

This field is required

Middle Name

Last Name *

This field is required

Phone Number

I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *

You must agree to be contacted to continue.

Please call me during the day.

Please call me during the evening.

Message

Return to Search

Research

UR Health Research

Expanded Access Program of Ponatinib

Basic Study Information

Study Contact Information

Additional Study Details

Contact This Study

Trial Not Found